×
About 46,355 results

ALLMedicine™ Ovarian Cancer Center

Research & Reviews  15,532 results

Regression of Breast Cancer Metastases Following Treatment with Irradiated SV-BR-1-GM, ...
https://doi.org/10.2174/1574892817666220518123331
Recent Patents on Anti-cancer Drug Discovery; Wiseman CL, Kharazi A et. al.

May 21st, 2022 - SV-BR-1-GM, derived from a patient with grade 2 (moderately differentiated) breast cancer, is a GM-CSF-secreting breast cancer cell line with properties of antigen-presenting cells. SV-BR-1-GM and next-generation versions are covered by several pe...

Predictors of Relapse of Ovarian, Peritoneal, and Fallopian Tube Cancers
https://clinicaltrials.gov/ct2/show/NCT00086567

May 20th, 2022 - Background: Over 80% of patients with advanced stage epithelial ovarian cancer will relapse Serum biomarkers are needed for predictors of persistent disease and relapse CA-125 is a less than satisfactory clinical tool for detecting relapse A serum...

Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer
https://clinicaltrials.gov/ct2/show/NCT00040222

May 20th, 2022 - Individuals and families with known or suspected syndromes that include breast, ovarian or genetically-related cancers are enrolled in this family study, which is a syndrome-specific sub-set of the long-standing DCEG Human Genetics Program umbrell...

Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Trip...
https://clinicaltrials.gov/ct2/show/NCT02484404

May 20th, 2022 - Background: Disruption of the immune checkpoint PD-1/PD-L1 pathway yielded clinical activity in subsets of advanced solid tumors, such as melanoma and lung cancer. Olaparib (O), a PARP inhibitor (PARPi), has demonstrated single agent activity in r...

Blood Collection From People With Ovarian Cancer
https://clinicaltrials.gov/ct2/show/NCT02063464

May 20th, 2022 - Background: Using both in vitro and in vivo assays we have shown that human monocytes primed with Interferons alpha and gamma are tumoricidal and are capable of killing a number of tumor cell lines and human tumors implanted into immunocompromised...

see more →

Guidelines  54 results

Risk-Reducing Salpingo-Oophorectomy and the Use of Hormone Replacement Therapy Below th...
https://doi.org/10.1111/1471-0528.16896
BJOG : an International Journal of Obstetrics and Gynaeco... Manchanda R, Gaba F et. al.

Oct 22nd, 2021 - This paper deals with the use of hormone replacement therapy (HRT) after the removal of fallopian tubes and ovaries to prevent ovarian cancer in premenopausal high risk women. Some women have an alteration in their genetic code, which makes them m...

Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2021.0007
Journal of the National Comprehensive Cancer Network : JN... Armstrong DK, Alvarez RD et. al.

Feb 6th, 2021 - Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States and is the country's fifth most common cause of cancer mortality in women. A major challenge in treating ovarian cancer is that most patients have...

SEOM clinical guideline in ovarian cancer (2020).
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8058000
Clinical & Translational Oncology : Official Publication ... Redondo A, Guerra E et. al.

Jan 31st, 2021 - Despite remarkable advances in the knowledge of molecular biology and treatment, ovarian cancer remains the leading cause of death from gynecologic cancer. In the last decade, there have been important advances both in systemic and surgical treatm...

Breastfeeding Challenges: ACOG Committee Opinion, Number 820.
https://doi.org/10.1097/AOG.0000000000004253
Obstetrics and Gynecology;

Jan 23rd, 2021 - Breastfeeding is associated with a decrease in a woman's risk of breast cancer, ovarian cancer, diabetes mellitus, and hypertensive heart disease. Breastfeeding initiation rates in the United States are increasing, and many women are aware of the ...

Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021,...
https://doi.org/10.6004/jnccn.2021.0001
Journal of the National Comprehensive Cancer Network : JN... Daly MB, Pal T et. al.

Jan 7th, 2021 - The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic focus primarily on assessment of pathogenic or likely pathogenic variants associated with increased risk of breast, ovarian, and pancreatic cancer and r...

see more →

Drugs  83 results see all →

Clinicaltrials.gov  653 results

Predictors of Relapse of Ovarian, Peritoneal, and Fallopian Tube Cancers
https://clinicaltrials.gov/ct2/show/NCT00086567

May 20th, 2022 - Background: Over 80% of patients with advanced stage epithelial ovarian cancer will relapse Serum biomarkers are needed for predictors of persistent disease and relapse CA-125 is a less than satisfactory clinical tool for detecting relapse A serum...

Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer
https://clinicaltrials.gov/ct2/show/NCT00040222

May 20th, 2022 - Individuals and families with known or suspected syndromes that include breast, ovarian or genetically-related cancers are enrolled in this family study, which is a syndrome-specific sub-set of the long-standing DCEG Human Genetics Program umbrell...

Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Trip...
https://clinicaltrials.gov/ct2/show/NCT02484404

May 20th, 2022 - Background: Disruption of the immune checkpoint PD-1/PD-L1 pathway yielded clinical activity in subsets of advanced solid tumors, such as melanoma and lung cancer. Olaparib (O), a PARP inhibitor (PARPi), has demonstrated single agent activity in r...

Blood Collection From People With Ovarian Cancer
https://clinicaltrials.gov/ct2/show/NCT02063464

May 20th, 2022 - Background: Using both in vitro and in vivo assays we have shown that human monocytes primed with Interferons alpha and gamma are tumoricidal and are capable of killing a number of tumor cell lines and human tumors implanted into immunocompromised...

C-PATROL - Non-interventional Study (NIS) to Collect Clinical and Patient Reported Outcome Data in an Olaparib Treated BRCAm+ PSR Ovarian Cancer Population
https://clinicaltrials.gov/ct2/show/NCT02503436

May 19th, 2022 - The main objective of the proposed non-interventional study is to obtain real-world effectiveness, safety and treatment patterns data of patients with BRCAm+ (Breast Cancer Gene(s) mutation positive) platinum sensitive relapsed (PSR) ovarian cance...

see more →

News  2,197 results

DNA Alterations and Selection of PARP Inhibitors in mCRPC
https://www.onclive.com/view/dna-alterations-and-selection-of-parp-inhibitors-in-mcrpc

May 6th, 2022 - Transcript: Alicia Morgans, MD, MPH: I want to pick up on one of the threads that you dropped related to differential responsiveness of particular alterations in patients to specific PARP inhibitors. I think this is a question that remains one of...

FDA Rejects More China Drugs; Clue to Uterine Ca Disparity; Cancer-Vax Controversy
https://www.medpagetoday.com/hematologyoncology/othercancers/98587

May 6th, 2022 - China-based Hutchmed announced receipt of a complete response letter from the FDA, stating that the agency cannot approve the tyrosine kinase inhibitor surufatinib for advanced neuroendocrine tumors without support from a multiregional clinical tr...

Genomic Testing Challenges Persist
https://www.onclive.com/view/genomic-testing-challenges-persist

May 5th, 2022 - Although molecular biomarkers are becoming increasingly relevant in cancer care, community oncologists confront a plethora of challenges in translating research findings into practice. Structural changes in payment systems and decision-support too...

JDQ443 Demonstrates Early Efficacy Signals in KRAS G12C-Mutant Solid Tumors
https://www.onclive.com/view/jdq443-demonstrates-early-efficacy-signals-in-kras-g12c-mutant-solid-tumors

May 2nd, 2022 - The novel KRAS G12C inhibitor, JDQ443, demonstrated early efficacy signals and a tolerable safety profile in initial data from the dose-escalation portion of the phase 1b/2 KontRASt-01 (NCT04699188) trial presented at the 2022 AACR Annual Meeting....

Phase 3 Trial Seeks to Confirm Oregovomab Benefit in Advanced Ovarian Cancer
https://www.onclive.com/view/phase-3-trial-seeks-to-confirm-oregovomab-benefit-in-advanced-ovarian-cancer

May 2nd, 2022 - Oregovomab (OvaRex), an investigational monoclonal antibody with promising phase 2 data, is being tested in combination with paclitaxel for patients with advanced epithelial ovarian cancer in the phase 3 FLORA-5trial (QPT-ORE-005), which was highl...

see more →

Patient Education  23 results see all →